Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HCW Biologics ( (HCWB) ) has shared an update.
On March 17, 2026, HCW Biologics Inc., a U.S.-based commercial- and clinical-stage biopharmaceutical company developing fusion immunotherapies for autoimmune disease, cancer and senescence-associated dysplasia, reported it had received full payment of a $7.0 million upfront license fee for its molecule HCW11-006. The consideration comprises $3.5 million in cash and a $3.5 million minority co-founder equity stake in Beijing Trimmune Biotech, a new China-focused development and commercialization vehicle backed by investors including CITIC Medical Fund and TigerYeah Capital.
The exclusive worldwide license for HCW11-006 shifts Phase 1 clinical development costs in China to Trimmune, with a first-in-human study there expected to start in the first half of 2027 and with HCW Biologics eligible for future development milestones, double-digit royalties and a share of any downstream transactions. Strategically, the deal secures non-dilutive funding and regional partnership leverage for HCW Biologics, including a no-cost option to reclaim rights for in vivo applications in the Americas after Phase 1 and potential additional payments if Trimmune opts to license regional China rights to HCW9302, the company’s lead autoimmune asset currently in a Phase 1 trial for alopecia areata.
The most recent analyst rating on (HCWB) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.
Spark’s Take on HCWB Stock
According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.
The score is held down primarily by very weak financial performance (sharp revenue decline, negative gross profit in TTM, persistent cash burn, and negative equity). Technicals also remain unfavorable with price below key longer-term moving averages and negative MACD. Offsetting factors are limited to positive corporate developments (financing/liability settlement to bolster equity and a Phase 1 trial start), which improve near-term positioning but do not yet change the fundamental risk profile.
To see Spark’s full report on HCWB stock, click here.
More about HCW Biologics
HCW Biologics Inc. is a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapies to treat autoimmune diseases, cancer, and senescence-associated dysplasia. Its pipeline includes HCW9206 for CAR-T cell generation, lead autoimmune candidate HCW9302 in Phase 1 for alopecia areata, and preclinical T-cell engagers and checkpoint inhibitors built on proprietary TOBI and TRBC platforms.
The company targets proinflammatory and senescence-associated conditions driven by chronic inflammation, aiming to improve quality of life and potentially extend longevity. HCW Biologics pursues a business development-led strategy and has already entered into two licensing deals granting exclusive worldwide rights for certain proprietary molecules, positioning partnerships as a key pillar of its clinical development and financing plans.
Average Trading Volume: 7,890,856
Technical Sentiment Signal: Sell
Current Market Cap: $5.38M
Learn more about HCWB stock on TipRanks’ Stock Analysis page.